BioMarin Pharmaceutical has named Cara Bauer, Ph.D., as its new Executive Vice President and Chief People Officer, effective October 5, 2026. Bauer brings over 25 years of human resources experience in biotechnology and technology sectors, previously serving at Kyverna Therapeutics and Gilead's Kite. She succeeds Amy Wireman, who is retiring but will stay on in an advisory role to support the transition. Bauer's expertise in scaling organizations and talent development is expected to strengthen BioMarin's culture and innovation focus as the company continues advancing treatments for rare genetic diseases.
BioMarin's leadership change is noted here with Pluang's health sector data as context. For readers following health stocks, 61 of 100 US health-sector stocks rose while 38 fell on Pluang. Notable movers included DNA at USD 14.99 with a 21.38% increase, NVAX at USD 12.55 up 19.98%, and RXRX at USD 4.76 rising 15.53%, as of Oct 06, 2026 03:02 WIB.
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
